Business Wire

Lineage Logistics Celebrates the Grand Opening of Savannah Fresh-Port Wentworth Facility

20.4.2023 20:30:00 EEST | Business Wire | Press release

Share

Lineage Logistics (“Lineage” or the “Company”), one of the leading temperature-controlled industrial REITs and integrated solutions providers worldwide, today celebrated the grand opening of its newest facility in Port Wentworth, Georgia. Savannah Fresh-Port Wentworth is strategically located near the Port of Savannah, the largest single-terminal container facility of its kind in North America and the third busiest container gateway in the U.S.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230420005218/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Lineage Logistics' Savannah Fresh-Port Wentworth facility is strategically located near the Port of Savannah and will allow Lineage to process up to 1.4 million pounds of produce per day. (Photo: Business Wire)

The 220,000-square-foot facility offers cross-docking services for products to enter and exit the facility on the same day if needed, reducing storage time, creating cost efficiencies, and ensuring consumers receive fresh produce faster. The facility has 23 inbound and outbound lanes that can process more than 40 trucks daily, moving up to 1.4 million pounds of produce per day.

“Today, the demand for port-centric temperature-controlled storage has never been greater and our Fresh solution offerings at Lineage have never been more robust. Savannah Fresh-Port Wentworth will allow us to expand our Fresh offering to new and existing customers and also provides the needed capacity to improve market conditions,” said Jim Henderson, Vice President of Global Sales and Business Development at Lineage. “The opening of this new facility is a critical step for Lineage as we continuously work to reimagine the world’s food supply chain. We are honored to further our long-standing partnership with Georgia Ports Authority and look forward to building our presence in the state of Georgia, an essential hub for trade and innovation.”

For the past two years, Lineage has worked closely with the Savannah Economic Development Authority, Georgia Ports Authority, and the city of Port Wentworth to construct the Savannah Fresh-Port Wentworth facility in addition to its port-adjacent facility on Tremont Road in Savannah. The Savannah Fresh-Port Wentworth project resulted in a $78 million investment alone that created 65 new jobs, bringing Lineage’s total economic investment in Chatham County to over $100 million. To date, Lineage’s footprint in Georgia spans over 3 million sq. ft.

Savannah Fresh-Port Wentworth was designed to address the overwhelming influx in imports of fresh produce to ports in the Mid-Atlantic that lack the space to keep up with the demand. With proximity to the Port of Savannah, the new facility will enable Lineage to deliver larger quantities of fresh produce more efficiently to serve customers across the Southeast.

“With increasing demand for fresh produce capacity in Savannah, this new, state of the art facility is a welcome addition,” said Griff Lynch, Executive Director of the Georgia Ports Authority. “Lineage Logistics’ suite of services, such as cold-retreatment and onsite CBP inspections, will save time, help prevent loss and, ultimately, bring fresh food to market faster.”

Leaders from Lineage, business partners from the state of Georgia, community leaders from the city of Port Wentworth, and leadership from Georgia Ports Authority attended the facility’s grand opening.

About Lineage Logistics

Lineage is one of the leading temperature-controlled industrial REITs and integrated solutions providers worldwide. It has a global network of over 400 strategically located facilities totaling over 2 billion cubic feet of capacity which spans 20 countries across North America, Europe, and Asia-Pacific. Lineage has industry-leading expertise in end-to-end logistical solutions, an unrivaled real estate network, and develops and deploys innovative technology. This helps increase distribution efficiency, advance sustainability, minimize supply chain waste, and most importantly, as a Visionary Partner of Feeding America, helps feed the world. In recognition of the Company’s leading innovations and sustainability initiatives, Lineage was listed as No. 3 in the 2022 CNBC Disruptor 50 list, named a Deloitte US Best Managed Company in 2022, the No. 1 Data Science company, and 23rd overall on Fast Company’s 2019 list of The World’s Most Innovative Companies, in addition to being included on Fortune’s Change the World list in 2020. (www.lineagelogistics.com)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lineage Logistics
Christina Wiese
734-608-1855
cwiese@lineagelogistics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 18:16:00 EEST | Press release

Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor

Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 17:28:00 EEST | Press release

With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f

Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 16:00:00 EEST | Press release

Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading transformative and meaningful customer experiences. These leading organizations are turning everyday interactions into seamless, cross-channel journeys that deliver meaningful business impact and

Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 16:00:00 EEST | Press release

Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On the demand side, with smart meter integration, Predict+ models each meter individually and performs extensive calculations on actual, historical, and average data to acc

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 15:30:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye